Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Investors put $18.5mm into Intradigm through Series B

Executive Summary

Intradigm (RNAi-based cancer therapeutics) raised $18.5mm through its Series B round. New investor Lilly Ventures (who also joins the company's board) led and was joined by other first-time buyers Roche Venture Fund and MP Healthcare Venture Management (a jointly owned investment venture of Mitsubishi Chemical and its Mitsubishi Tanabe Pharma division). Returning backers Frazier Healthcare Ventures, Alta Partners, MediBic Alliance Technology Fund, and Novartis Venture Fund also participated.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Antisense, Oligonucleotides
    • Gene Therapy, Cell Therapy
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies